Haemonetics Corporation (NYSE: HAE) Stock Competitors & Peer Comparison
See HAE's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HAE and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HAE | $78.78 | +1.78% | 3.6B | 15.86 | $4.97 | N/A |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
HAE vs BDX Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas BDX's P/E ratio is 11.62. In terms of profitability, HAE's ROE is +0.11%, compared to BDX's ROE of +0.05%. Regarding short-term risk, HAE is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for HAE.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
HAE vs BDXA Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas BDXA's P/E ratio is 45.70. In terms of profitability, HAE's ROE is +0.11%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, HAE is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for HAE.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
HAE vs MDLN Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas MDLN's P/E ratio is 45.06. In terms of profitability, HAE's ROE is +0.11%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, HAE is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for HAE.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
HAE vs WST Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas WST's P/E ratio is 41.19. In terms of profitability, HAE's ROE is +0.11%, compared to WST's ROE of +0.19%. Regarding short-term risk, HAE is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for HAE.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
HAE vs HOLX Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas HOLX's P/E ratio is 31.54. In terms of profitability, HAE's ROE is +0.11%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, HAE is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for HAE.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
HAE vs COO Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas COO's P/E ratio is 15.42. In terms of profitability, HAE's ROE is +0.11%, compared to COO's ROE of +0.03%. Regarding short-term risk, HAE is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for HAE.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
HAE vs BDXB Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas BDXB's P/E ratio is 7.60. In terms of profitability, HAE's ROE is +0.11%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, HAE is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for HAE.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
HAE vs BAX Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas BAX's P/E ratio is 10.77. In terms of profitability, HAE's ROE is +0.11%, compared to BAX's ROE of -0.16%. Regarding short-term risk, HAE is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for HAE.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
HAE vs ATR Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas ATR's P/E ratio is 23.13. In terms of profitability, HAE's ROE is +0.11%, compared to ATR's ROE of +0.14%. Regarding short-term risk, HAE is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for HAE.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
HAE vs AVTR Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas AVTR's P/E ratio is 13.46. In terms of profitability, HAE's ROE is +0.11%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, HAE is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for HAE.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
HAE vs RGEN Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas RGEN's P/E ratio is 73.31. In terms of profitability, HAE's ROE is +0.11%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, HAE is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for HAE.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
HAE vs TFX Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas TFX's P/E ratio is 12.32. In terms of profitability, HAE's ROE is +0.11%, compared to TFX's ROE of -0.28%. Regarding short-term risk, HAE is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for HAE.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
HAE vs BLCO Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas BLCO's P/E ratio is 24.88. In terms of profitability, HAE's ROE is +0.11%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, HAE is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for HAE.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
HAE vs STVN Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas STVN's P/E ratio is 31.81. In terms of profitability, HAE's ROE is +0.11%, compared to STVN's ROE of +0.10%. Regarding short-term risk, HAE is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for HAE.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
HAE vs MMSI Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas MMSI's P/E ratio is 19.01. In terms of profitability, HAE's ROE is +0.11%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, HAE is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for HAE.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
HAE vs ICUI Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas ICUI's P/E ratio is 19.66. In terms of profitability, HAE's ROE is +0.11%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, HAE is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for HAE.Check ICUI's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
HAE vs XRAY Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas XRAY's P/E ratio is 9.04. In terms of profitability, HAE's ROE is +0.11%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, HAE is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for HAE.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
HAE vs LMAT Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas LMAT's P/E ratio is 37.05. In terms of profitability, HAE's ROE is +0.11%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, HAE is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for HAE.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
HAE vs PLSE Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas PLSE's P/E ratio is -27.48. In terms of profitability, HAE's ROE is +0.11%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, HAE is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for HAE.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
HAE vs ATRC Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, HAE's ROE is +0.11%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, HAE is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for HAE.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
HAE vs BLFS Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas BLFS's P/E ratio is -141.85. In terms of profitability, HAE's ROE is +0.11%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, HAE is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for HAE.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
HAE vs AZTA Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas AZTA's P/E ratio is 60.82. In terms of profitability, HAE's ROE is +0.11%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, HAE is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for HAE.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
HAE vs KMTS Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas KMTS's P/E ratio is -8.92. In terms of profitability, HAE's ROE is +0.11%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, HAE is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for HAE.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
HAE vs STAA Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas STAA's P/E ratio is 41.02. In terms of profitability, HAE's ROE is +0.11%, compared to STAA's ROE of -0.06%. Regarding short-term risk, HAE is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for HAE.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
HAE vs QDEL Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas QDEL's P/E ratio is 11.98. In terms of profitability, HAE's ROE is +0.11%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, HAE is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for HAE.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
HAE vs ATRI Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas ATRI's P/E ratio is 64.50. In terms of profitability, HAE's ROE is +0.11%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, HAE is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for HAE.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
HAE vs ANGO Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas ANGO's P/E ratio is -34.85. In terms of profitability, HAE's ROE is +0.11%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, HAE is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for HAE.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
HAE vs NNNN Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas NNNN's P/E ratio is 145.38. In terms of profitability, HAE's ROE is +0.11%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, HAE is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for HAE.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
HAE vs OSUR Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas OSUR's P/E ratio is -4.78. In terms of profitability, HAE's ROE is +0.11%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, HAE is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for HAE.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
HAE vs SMTI Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas SMTI's P/E ratio is -426.00. In terms of profitability, HAE's ROE is +0.11%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, HAE is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for HAE.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
HAE vs UTMD Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas UTMD's P/E ratio is 19.86. In terms of profitability, HAE's ROE is +0.11%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, HAE is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for HAE.Check UTMD's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
HAE vs INFU Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas INFU's P/E ratio is 23.97. In terms of profitability, HAE's ROE is +0.11%, compared to INFU's ROE of +0.14%. Regarding short-term risk, HAE is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for HAE.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
HAE vs KRMD Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas KRMD's P/E ratio is -95.75. In terms of profitability, HAE's ROE is +0.11%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, HAE is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for HAE.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
HAE vs PDEX Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas PDEX's P/E ratio is 19.34. In terms of profitability, HAE's ROE is +0.11%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, HAE is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for HAE.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
HAE vs MBOT Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas MBOT's P/E ratio is -6.58. In terms of profitability, HAE's ROE is +0.11%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, HAE is less volatile compared to MBOT. This indicates lower risk in terms of short-term price fluctuations for HAE.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
HAE vs AKYA Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas AKYA's P/E ratio is -1.34. In terms of profitability, HAE's ROE is +0.11%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, HAE is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for HAE.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
HAE vs STSS Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas STSS's P/E ratio is -0.02. In terms of profitability, HAE's ROE is +0.11%, compared to STSS's ROE of -1.66%. Regarding short-term risk, HAE is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for HAE.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
HAE vs DXR Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas DXR's P/E ratio is 27.33. In terms of profitability, HAE's ROE is +0.11%, compared to DXR's ROE of +0.22%. Regarding short-term risk, HAE is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for HAE.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
HAE vs OMIC Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas OMIC's P/E ratio is -0.58. In terms of profitability, HAE's ROE is +0.11%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, HAE is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for HAE.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
HAE vs IGAP Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas IGAP's P/E ratio is -10.52. In terms of profitability, HAE's ROE is +0.11%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, HAE is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for HAE.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
HAE vs NEPH Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas NEPH's P/E ratio is 50.86. In terms of profitability, HAE's ROE is +0.11%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, HAE is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for HAE.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
HAE vs MLSS Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas MLSS's P/E ratio is -6.50. In terms of profitability, HAE's ROE is +0.11%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, HAE is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for HAE.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
HAE vs POCI Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas POCI's P/E ratio is -6.07. In terms of profitability, HAE's ROE is +0.11%, compared to POCI's ROE of -0.37%. Regarding short-term risk, HAE is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for HAE.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
HAE vs SDC Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas SDC's P/E ratio is -0.03. In terms of profitability, HAE's ROE is +0.11%, compared to SDC's ROE of -1.96%. Regarding short-term risk, HAE is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for HAE.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
HAE vs HBIO Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas HBIO's P/E ratio is -16.81. In terms of profitability, HAE's ROE is +0.11%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, HAE is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for HAE.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
HAE vs IVC Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas IVC's P/E ratio is -0.79. In terms of profitability, HAE's ROE is +0.11%, compared to IVC's ROE of -0.46%. Regarding short-term risk, HAE is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for HAE.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
HAE vs RVP Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas RVP's P/E ratio is -2.06. In terms of profitability, HAE's ROE is +0.11%, compared to RVP's ROE of -0.08%. Regarding short-term risk, HAE is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for HAE.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
HAE vs ZJYL Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, HAE's ROE is +0.11%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, HAE is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for HAE.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
HAE vs FEMY Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas FEMY's P/E ratio is -10.25. In terms of profitability, HAE's ROE is +0.11%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, HAE is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for HAE.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
HAE vs RGNT Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas RGNT's P/E ratio is -0.08. In terms of profitability, HAE's ROE is +0.11%, compared to RGNT's ROE of N/A. Regarding short-term risk, HAE is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for HAE.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
HAE vs NSTG Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas NSTG's P/E ratio is -0.03. In terms of profitability, HAE's ROE is +0.11%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, HAE is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for HAE.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
HAE vs NXGL Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas NXGL's P/E ratio is -1.13. In terms of profitability, HAE's ROE is +0.11%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, HAE is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for HAE.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
HAE vs POAI Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas POAI's P/E ratio is -0.03. In terms of profitability, HAE's ROE is +0.11%, compared to POAI's ROE of -107.05%. Regarding short-term risk, HAE is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for HAE.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
HAE vs LUCY Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas LUCY's P/E ratio is -0.39. In terms of profitability, HAE's ROE is +0.11%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, HAE is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for HAE.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
HAE vs MHUA Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas MHUA's P/E ratio is 0.25. In terms of profitability, HAE's ROE is +0.11%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, HAE is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for HAE.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
HAE vs NXGLW Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, HAE's ROE is +0.11%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, HAE is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for HAE.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
HAE vs GMVD Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas GMVD's P/E ratio is -0.01. In terms of profitability, HAE's ROE is +0.11%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, HAE is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for HAE.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
HAE vs GMVDW Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas GMVDW's P/E ratio is N/A. In terms of profitability, HAE's ROE is +0.11%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, HAE is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for HAE.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
HAE vs AVGR Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas AVGR's P/E ratio is -0.05. In terms of profitability, HAE's ROE is +0.11%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, HAE is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for HAE.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
HAE vs LUCYW Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, HAE's ROE is +0.11%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, HAE is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for HAE.Check LUCYW's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
HAE vs GCTK Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas GCTK's P/E ratio is -0.01. In terms of profitability, HAE's ROE is +0.11%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, HAE is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for HAE.Check GCTK's competition here
Apria, Inc. (NASDAQ: APR)
HAE vs APR Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, APR has a market cap of 0. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas APR's P/E ratio is 22.59. In terms of profitability, HAE's ROE is +0.11%, compared to APR's ROE of +9.81%. Regarding short-term risk, HAE is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for HAE.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
HAE vs IIN Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, IIN has a market cap of 0. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas IIN's P/E ratio is 226.45. In terms of profitability, HAE's ROE is +0.11%, compared to IIN's ROE of -0.00%. Regarding short-term risk, HAE is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for HAE.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
HAE vs ALOG Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas ALOG's P/E ratio is 40.93. In terms of profitability, HAE's ROE is +0.11%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, HAE is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for HAE.Check ALOG's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
HAE vs ATRS Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas ATRS's P/E ratio is 14.95. In terms of profitability, HAE's ROE is +0.11%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, HAE is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for HAE.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
HAE vs IVTY Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas IVTY's P/E ratio is -3.80. In terms of profitability, HAE's ROE is +0.11%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, HAE is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for HAE.Check IVTY's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
HAE vs HRC Comparison July 2026
Haemonetics Corporation (NYSE: HAE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HAE stands at 3.6B. In comparison, HRC has a market cap of 0. Regarding current trading prices, HAE is priced at $78.78 on the NYSE, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HAE currently has a P/E ratio of 15.86, whereas HRC's P/E ratio is 41.92. In terms of profitability, HAE's ROE is +0.11%, compared to HRC's ROE of +0.14%. Regarding short-term risk, HAE is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for HAE.Check HRC's competition here